| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 4 | +568K | 98.1% | $40.03 | +$22.8M |
| Sells | 1 | -11K | 1.9% | $41.79 | -$460K |
| Net | +3 | +557K | 96.2% | +$22.3M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| John W. Childs | Director | $308M | +$12M | +4.06% | Oct 2, 2024 |
| Vlad Coric | Chief Executive Officer, Director | $150M | +$6M | +4.15% | Oct 2, 2024 |
| Gregory Bailey | Director | $71.6M | +$3.73M | +5.5% | Sep 24, 2024 |
| Matthew Buten | Chief Financial Officer | $4.17M | Jan 2, 2024 | ||
| Bruce Car | Chief Scientific Officer | $1.09M | +$1.01M | +1259% | Jun 17, 2024 |
| Irina Antonijevic | Director | $106K | -$460K | -81.3% | Apr 30, 2024 |
| Kishan Mehta | Director | Apr 30, 2024 | |||
| George Clark | VP, Chief Accounting Officer | Jan 2, 2024 | |||
| Robert J. Hugin | Director | Apr 30, 2024 | |||
| Michael Thomas Heffernan | Director | Apr 30, 2024 | |||
| Biohaven Pharmaceutical Holding Co Ltd. | 10%+ Owner | Oct 3, 2022 | |||
| Julia P. Gregory | Director | Apr 30, 2024 | |||
| Kimberly Gentile | SVP, Clinical Operations | Jan 2, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|